Inmune Bio Files 8-K Report
Ticker: INMB · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, regulatory
Related Tickers: INMB
TL;DR
INMB filed an 8-K, looks like standard procedure, no major news.
AI Summary
On July 25, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific new material events or financial figures detailed in the provided text. The report confirms the company's identity, location in Boca Raton, Florida, and its standard industrial classification as Biological Products.
Why It Matters
This 8-K filing serves as a routine update for investors, confirming the company's operational status and filing requirements without disclosing new material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain new material information that would immediately impact risk.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- July 25, 2024 (date) — Date of earliest event reported
- Boca Raton, Florida (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Inmune Bio, Inc.?
The primary purpose of this 8-K filing is to report on "Other Events" and "Financial Statements and Exhibits," serving as a current report as per SEC regulations.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on July 25, 2024.
Where are Inmune Bio, Inc.'s principal executive offices located?
Inmune Bio, Inc.'s principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is Inmune Bio, Inc.'s Standard Industrial Classification (SIC) code and description?
Inmune Bio, Inc.'s SIC code is 2836, with the description BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Does this 8-K filing disclose any new financial results or material business developments?
Based on the provided text, this 8-K filing does not appear to disclose any new specific financial results or material business developments; it seems to be a procedural filing.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2024-07-30 16:00:20
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0210183-8k_inmune.htm (8-K) — 23KB
- ea021018301ex99-1_inmune.htm (EX-99.1) — 10KB
- 0001013762-24-002642.txt ( ) — 207KB
- inmb-20240725.xsd (EX-101.SCH) — 3KB
- inmb-20240725_lab.xml (EX-101.LAB) — 33KB
- inmb-20240725_pre.xml (EX-101.PRE) — 22KB
- ea0210183-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On July 25, 2024, INmune Bio Inc. issued a press release announcing it will host a conference call on Thursday, August 1, 2024 at 4:30 p.m., Eastern Time to discuss results for its quarter ended June 30, 2024, and to provide a corporate update. A copy of the press release is attached herewith as Exhibit 99.1.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated July 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: July 30, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2